Navigation Links
Media invitation: 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics

Journalists are invited to attend the 20th EORTCNCIAACR Symposium on "Molecular Targets and Cancer Therapeutics" in Geneva, Switzerland [Geneva Palexpo, Geneva] from Tuesday 21 October-Friday 24 October.

Today (Monday 15 September) is the deadline for booking accommodation via the official local agent if you wish to attend this symposium, organised jointly by the European Organisation for the Research and Treatment of Cancer, the US National Cancer Institute and the American Association for Cancer Research.

The symposium offers:

  • Cutting edge information on new cancer drug research and development from experts in Europe, North America, Asia and Australia;
  • Free registration for bona fide media with official press credentials (press card and/or a commissioning letter from the editor of the journal/website they represent);
  • All sessions open to journalists;
  • Media centre with free computing, fax, international phone, internet and photocopying facilities;
  • Two news briefings (12.15 hrs CEST: Wednesday 22 October and Thursday 23 October)

Topics at the news briefings or to be press released include:

  • Crossing the blood-brain barrier: scientists develop a new drug delivery system for hard-to-treat cancers of the central nervous system;
  • New "spindle poisoning" drug shows promise in phase I trial of solid tumours: phase II trials planned;
  • Scientists discover pattern of gene expression that predicts response to treatment in advanced colorectal cancer;
  • New drug shows impressive activity in patients with advanced disease, including medullary thyroid cancer. Phase III trials planned;
  • Researchers discover that a genetic mutation makes metastatic colorectal cancer patients resistant to anti-EGFR drugs. Potential for a biomarker to select patients who would respond to treatment;
  • Cancer vaccine shows promise in patients with bowel, kidney and prostate cancer: phase III trials on-going.

Please note: the details contained in this media alert are for information only and are embargoed until the time of the news briefings or press releases.

The symposium is an opportunity for journalists to listen and talk to some of the 2,200 European, American and other international experts in oncology gathered in Geneva to share findings on the latest research on new molecular targets, designer diagnostics and prognostics, smart drugs and other novel approaches to cancer treatment.

NB: the official language of the symposium is English and all press materials will be in English.

Journalists should register to attend the symposium by downloading a registration form at: or by contacting Riitta Kettunen:
Tel: +32 2 775 02 05
Fax: +32 2 775 02 00

More information on the programme and hotel accommodation is available on the EORTC-NCI-AACR symposium website at:


This should be booked through Symporg SA, the official local agent for the symposium, via the symposium website. Symporg, SA
Tel: +41-22 839 84 84
Fax: +41-22 839 84 85

NB: the deadline for hotel reservations is September 15. Reservations are made on a first-come, first served basis and you are advised to book early.


Contact: Emma Mason
ECCO-the European CanCer Organisation

Related biology news :

1. September Geology and GSA Today media highlights
2. Heart of Herschel to be presented to media
3. Last chance for media to register for ECCO 14 -- the European Cancer Conference
4. October Geology and GSA Today media highlights
5. Media highlights in the November issues of Biophysical Journal
6. November GEOLOGY and GSA TODAY Media Highlights
7. Nanotechnology and the media: The inside story
8. December GEOLOGY and GSA TODAY media highlights
9. Better protection for biomedial devices could result from Rutgers-Camden research
10. Media highlights in the Dec. 15 issue of Biophysical Journal
11. Immediate action needed to save corals from climate change
Post Your Comments:
(Date:6/2/2016)... The Weather Company , an IBM Business (NYSE: IBM ... which consumers will be able to interact with IBM Watson ... or text and receive relevant information about the product or ... long sought an advertising solution that can create a one-to-one ... valuable; and can scale across millions of interactions and touchpoints. ...
(Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... OTTAWA, ON (PRWEB) , ... June 23, 2016 , ... ... former DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA ... joining the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
Breaking Biology Technology: